Akebia Therapeutics Inc (FRA:AX9)
€ 1.642 0.149 (9.98%) Market Cap: 359.71 Mil Enterprise Value: 368.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q3 2021 Akebia Therapeutics Inc Earnings Call Transcript

Nov 09, 2021 / 02:00PM GMT
Release Date Price: €2.44 (-3.17%)
Operator

Good day, and thank you for standing by. Welcome to Akebia's Third Quarter 2021 Financial Results. (Operator Instructions)

With now, I would like to hand the conference over to your first speaker, Mercedes Carrasco. Thank you, and Please go ahead.

Mercedes Carrasco;Akebia Therapeutics;Director
Inc.;Corporate Communications,

Thank you, and welcome to Akebia's Third Quarter 2021 Financial Results and Business Update conference call. Please note that a press release was issued on Thursday, November 4, detailing our third quarter financial results, and that release is available on the Investors section of our website. For your convenience, a replay of today's call will also be available on our website shortly after we conclude.

Joining me for today's call, we have John Butler, our Chief Executive Officer; Dave Spellman, Chief Financial Officer; Dell Faulkingham, Chief Commercial Officer; as well as Dr. Steven Burke, our Head of R&D and Chief Medical Officer, who will be available for questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot